

Evaluation Report for Category L, Subcategory 1.2 Application

Application Number: 2022-3883

Application: Application Subject to Protection of Proprietary Interests in

Pesticide Data (PPIP) Policy – Equivalency/Data Compensation

Assessment

Product: Metrixx Plus

Registration Number: 35039

Active ingredients (a.i.): Metribuzin and chlorimuron-ethyl

PMRA Document Number: 3493502

Purpose of Application

The purpose of this application was to register Metrixx Plus, a new herbicide end-use product, based on a registered precedent product.

Chemistry Assessment

Metrixx Plus is formulated as a dry flowable containing metribuzin at a concentration of 70.4% and chlorimuron-ethyl at a concentration of 1.54%. This end-use product has a density of 0.591 – 0.637 g/mL and pH of 8.3. The required chemistry data for Metrixx Plus have been provided, reviewed and found to be acceptable.

Health Assessments

Metrixx Plus was considered toxicologically equivalent to the precedent product; therefore, no toxicology data were required. Metrixx Plus is considered to be of low acute toxicity via the oral, dermal, and inhalation routes. It is considered to be minimally irritating to the eye and slightly irritating to the skin. It is not considered to be a dermal sensitizer.

The use pattern of Metrixx Plus is comparable to the registered use pattern of the precedent product. Therefore, potential exposure for mixers, loaders, applicators, bystanders and postapplication workers is not expected to exceed the current exposure to the registered products of these active ingredients. No health risks of concern are expected for workers and bystanders when label directions, precautions and restrictions are followed.

No new residue data for metribuzin or chlorimuron-ethyl were submitted or are required to support the registration of Metrixx Plus. Previously reviewed residue data were re-assessed in the framework of this application.



The use directions on the Metrixx Plus label, including the target crops, method (ground), rates and timing of application, geographic restrictions, preharvest intervals, feeding restrictions, and crop rotation restrictions are comparable to those on the label of the precedent product.

Based on this assessment, residues are not expected to be greater than those from the currently registered uses and will be covered by the established maximum residue limits (MRLs). Consequently, dietary exposure to residues of metribuzin and chlorimuron-ethyl is not expected to increase with the registration of Metrixx Plus and will not pose health risks of concern to any segment of the population, including infants, children, adults and seniors.

Environmental Assessment

The use pattern for Metrixx Plus is within the currently registered use pattern for the precedent product. Risk to the environment is acceptable when Metrixx Plus is used according to the label directions.

Value Assessment

Registration of a generic product may increase product competition in the marketplace, which may in turn reduce purchasing costs of similar products.

Value information consisted of a comparison of the formulation of Metrixx Plus to that of the precedent product. Based on the weight of evidence, agronomic equivalence between Metrixx Plus and the precedent product was established. Therefore, all labelled uses and claims found on the precedent product label are supported for inclusion on the Metrixx Plus label.

Conclusion

The Pest Management Regulatory Agency has completed an assessment of the information provided, and has found the information acceptable to register Metrixx Plus.

References

Reference
2022, Metrixx Plus Manufacturing Process, DACO: 3.2.1,3.2.2,3.2.3,3.3.1 CBI
2022, Additional Product Chemistry for Sharda Metrixx Plus - Parent, DACO:
3.1.1,3.1.2,3.1.3,3.1.4,3.5.13,3.5.15,3.5.4,3.5.5,3.5.9
2022, Determination of Physico-Chemical Properties of Chlorimuron-Ethyl
1.54% + Metribuzin 70.4% DF Guidelines, DACO: 3.5.11,3.5.12,3.5.6,3.5.8
2022, Accelerated Storage Stability Test by Heating at 54 +/- 2C of Chlorimuron-
Ethyl 1.54% + Metribuzin 70.4% DF Guidelines, DACO:
3.4.1,3.4.2,3.5.1,3.5.10,3.5.14,3.5.2,3.5.3,3.5.7

© His Majesty the King in Right of Canada, as represented by the Minister of Health Canada, 2023

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.